Enhanced hair growth composition and enhanced hair growth method
A technology for hair growth and composition, applied in the field of compositions of length and density, capable of solving problems such as side effects, darkening of the iris, eye irritation, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0037] A randomized double-blind clinical trial was conducted on 34 healthy volunteers to evaluate the product, which has the structural name (z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R , E) Eyelash growth-promoting properties of synthetic prostaglandin analogs of -3-hydroxy-4-phenoxy-but-1-enyl)-cyclopentyl)-hept-5-enoic acid acetamide.
[0038] Prepare a placebo solution consisting of the following ingredients.
[0039] Each composition and its corresponding weight percent are as follows:
[0040] Composition Percentage
[0041] Pure water 96.099
[0042] Hydrolyzed Glycosaminoglycans 0.750
[0043] Phenoxyethanol 0.540
[0044] Triethanolamine 0.520
[0045] Acrylates C 10-30 Alkyl Acrylate Crosspolymer 0.500
[0046] C 12-15 Alkyl Benzoate 0.500
[0047] Caprylyl Glycol 0.430
[0048] Panthenol 0.250
[0050] Biotin 0.100
[0051] Sodium Lactate 0.087
[0052] Sodium pyrrolidone carboxylate (Sodium PCA) 0.032
[0053] Ethanol 0.030 ...
Embodiment 2
[0084] Randomized double-blind clinical trials were used to compare the compounds containing the active agent of the present invention (i.e. (z)-7-((1R, 2R, 3R, 5S)-3,5-dihydroxyl-2-((R, E)-3-hydroxyl - Effect of 4-phenoxy-but-1-enyl)-cyclopentyl)-hept-5-enoic acid acetamide), bimataprost, and placebo on eyelash length. After 4 weeks of use, different concentrations of the active agent of the present invention increased eyelash length by 49-62%, while bimataprost only increased eyelash length by 38% (see Table 1 for details). Independent ocular safety studies have shown that the active agent of the invention has no effect on intraocular pressure and is therefore safe for contact lens wearers and persons with sensitive eyes. Bimataprost, used in eye drops, reduces intraocular pressure in glaucoma patients.
[0085]Same as in Example 1, the control group described in Table 1 refers to the upper right eyelashes (N=34) of all testers who use solution A; the placebo group refers t...
Embodiment 3
[0089] The active agent of the invention (i.e. (z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2 -((R,E)-3-Hydroxy-4-phenoxy-but-1-enyl)-cyclopentyl)-hept-5-enoic acid acetamide). After 8 weeks of daily use, preliminary test data showed an average increase of about 20% in the transition from villous hair to terminal hair in 10 subjects, and subjectively reported visually visible localized hair growth.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 